MED20 is essential for early embryogenesis and regulates NANOG expression

Wei Cui^{1,2}, Chelsea Marcho¹, Yongsheng Wang³, Rinat Degani¹, Morgane Golan¹, Kimberly D Tremblay¹, Jaime A Rivera-Pérez⁴ and Jesse Mager¹

¹Department of Veterinary and Animal Sciences, University of Massachusetts, Amherst, Massachusetts, USA,

²Animal Models Core Facility, Institute for Applied Life Sciences (IALS), University of Massachusetts, Amherst, Massachusetts, USA, ³Key Laboratory of Animal Biotechnology of the Ministry of Agriculture, College of Veterinary Medicine, Northwest A&F University, Yangling, Shaanxi, PR China and ⁴Division of Genes and Development, Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts, USA

Correspondence should be addressed to W Cui or J Mager; Email: wcui@umass.edu or jmager@vasci.umass.edu

Abstract

Mediator is an evolutionarily conserved multi-subunit complex, bridging transcriptional activators and repressors to the general RNA polymerase II (Pol II) initiation machinery. Though the Mediator complex is crucial for the transcription of almost all Pol II promoters in eukaryotic organisms, the phenotypes of individual Mediator subunit mutants are each distinct. Here, we report for the first time, the essential role of subunit MED20 in early mammalian embryo development. Although *Med20* mutant mouse embryos exhibit normal morphology at E3.5 blastocyst stage, they cannot be recovered at early post-gastrulation stages. Outgrowth assays show that mutant blastocysts cannot hatch from the zona pellucida, indicating impaired blastocyst function. Assessments of cell death and cell lineage specification reveal that apoptosis, inner cell mass, trophoblast and primitive endoderm markers are normal in mutant blastocysts. However, the epiblast marker NANOG is ectopically expressed in the trophoblast of *Med20* mutants, indicative of defects in trophoblast specification. These results suggest that MED20 specifically, and the Mediator complex in general, are essential for the earliest steps of mammalian development and cell lineage specification.

Reproduction (2019) **157** 215–222

Introduction

Mammalian preimplantation development refers to the period from fertilization to implantation, during which the fertilized oocyte progresses through a number of cleavage divisions and three major transcriptional and morphogenetic events that lead to a blastocyst capable of implantation (Cockburn & Rossant 2010). The first well-defined event is the maternal-to-zygotic transition, which includes degradation of maternal mRNAs and replacement with zygotic transcripts. This dramatic reprogramming of gene expression is indispensable for establishment of totipotency and embryo development (Latham *et al.* 1991). The second major event is embryo compaction and polarization, and inheritance of cell polarity in daughter cells during subsequent divisions has been demonstrated as critical for solidification of cell-fate acquisition (Leung *et al.* 2016). The third critical event is blastomere outer/inner configuration and the first cell-fate allocation when the outer polar cells differentiate exclusively into the trophoblast (TE), whereas the apolar cells located inside the morula give rise to the inner cell mass (ICM) (Arnold & Robertson 2009). Well-characterized gene expression

patterns occur within these two distinct lineages. For example, the transcription factor (TF) OCT4 (also known as POU5F1) is enriched in ICM, while the TF CDX2 becomes highly expressed in TE (Nichols *et al.* 1998, Niwa *et al.* 2005). After the first cell-fate determination, when blastocysts reach more than 32 cells, the second cell-fate determination occurs, to segregate the ICM into epiblast (EPI) and primitive endoderm (PE). Well-defined profiles of gene expression demarcate these two populations. For example, NANOG only localizes to EPI cells, while TF SOX17 is expressed exclusively in PE lineage (Frum & Ralston 2015, Molotkov & Soriano 2018, Morgani *et al.* 2018). Finally, these three lineages EPI, PE and TE will contribute to the embryo, parietal yolk sac and placenta, respectively.

Although distinct localizations of TFs within ICM/TE and EPI/PE/TE lineages have been well illustrated, their upstream regulatory networks are not fully delineated (Lokken & Ralston 2016, Cui & Mager 2018). Among multiple signaling pathways involved in early cell-fate decisions, Hippo signaling was demonstrated to play a critical role through the analysis of mutant mouse embryos lacking TF TEA domain family member 4

(TEAD4) (Yagi *et al.* 2007). Other experiments also showed the indispensable role of Hippo signaling in the regulation of TE-specific TF CDX2 (Strumpf *et al.* 2005) and GATA3 (Ralston *et al.* 2010). Interestingly, recent studies indicate that Hippo signaling promotes ICM fate acquisition as well, though the regulatory mechanisms are still unknown (Wicklow *et al.* 2014). In addition to the Hippo pathway, the function of Notch signaling in TE lineage specification was also recently uncovered (Rayon *et al.* 2014). By using double knockouts for *Tead4* and the Notch effector *Rbpj*, Rayon *et al.* demonstrated Hippo and Notch signals converge on *Cdx2* to cooperatively promote TE lineage specification. Additional TFs continue to emerge as crucial regulators of early cell-fate decisions. For example, TFAP2C can directly regulate *Cdx2* expression through an enhancer in intron 1 during early cleavage stages to promote TE lineage specification (Cao *et al.* 2015). Although many other mechanisms, such as epigenetic regulation (Paul & Knott 2014, Marcho *et al.* 2015) and newly discovered genes (Cui *et al.* 2016a), contribute to and dictate these unique cellular identities, the full cadre of cellular mechanisms that controls these events remains unresolved.

Lineage specification and cell differentiation are complicated and highly regulated processes relying on the differential expression of various genes within distinct cell populations. For all eukaryote organisms and nearly all RNA polymerase II (Pol II) promoters, a crucial pathway to finely tune these regulatory signals and appropriate transcriptome activation is through the following: enhancer – activator – Mediator – Pol II – promoter (Kornberg 2005). As a core molecular signaling mechanism, the Mediator complex was originally identified in budding yeast (Kelleher *et al.* 1990), with subsequent identification of many protein subunits (25 in yeast and 30 in human) (Tsai *et al.* 2014). Functioning as the bridge, Mediator can convey regulatory signaling information to the basal RNA Pol II transcription machinery, eliciting both positive and negative regulation of gene transcription (Beyer *et al.* 2007). While the core Mediator complex seems to be universally required in all genes, subunit phenotypes can be distinct from one another, suggesting functional redundancy and specificity (Risley *et al.* 2010). Furthermore, although Mediator is evolutionarily conserved at the protein level, mutants in the same Mediator subunit can display dissimilar phenotypes in different organisms (Hentges 2011). Additionally, studies have confirmed that Mediator can interact with diverse TFs and co-factors to ensure that specific genes are expressed with appropriate temporal and cell type specificity (Yin & Wang 2014).

In the present study, we explored the role of MED20, one of the most conserved proteins in the Mediator complex, during mouse embryo development, using both knockout (KO) and knockdown (KD) strategies.

Our data show that MED20 is essential for hatching of the blastocyst from the zona pellucida. Moreover, outgrowth, apoptosis and lineage specification assays revealed that mutant blastocysts exhibit severe ectopic expression of NANOG, an epiblast marker, in the outer putative trophectoderm cells, demonstrating a failure to appropriately implant and establish the trophectoderm lineage.

Material and methods

Generation of *Med20* mutants

All animal experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of Massachusetts, Amherst (2015-0011, 2018-0003). *Med20* KO allele (C57BL/6NJ-Med20^{em1j>j}/J, Stock #: 027272) was generated on C57BL/6NJ background in The Jackson Laboratory (JAX) using CRISPR-Cas9 system, with two guide RNAs targeting AGGAACCTCTTGGGGACTGAT and GCTTAGAGTATTACGTTAA. The founder with 348bp deletion beginning in intron 1 at GGGGACTGATGGGTGGGGAT at Chromosome 17 positive strand position 47,612,827bp (GRCm38) and ending after GCTTAGAGTATTACGTTAA at position 47,613,174bp in intron 2 (Fig. 1A), which causes a short truncated protein with only 11 amino acids, was selected to establish the colony. To expand the colony, heterozygous (Het) mice from JAX were backcrossed again with C57BL/6NJ WT for the following heterozygous intercrosses to generate *Med20* mutants (Mut). Genotyping primers are used as follows (Fig. 1A): common forward primer for both WT allele and Mut allele: TGATGCCTTTGATTCCAACA; WT reverse: CACTCAATCCCCAACAGGT; Mut reverse: CCCTTGACAGAAAAGCAAGC.

Embryo recovery, culture and genotyping

Med20 heterozygous females aged 8–14 weeks were caged with *Med20* heterozygous males for natural matings, and the presence of a vaginal plug was defined as embryonic day 0.5 (E0.5). Embryos were then collected from uteri of heterozygous females by dissection or flushing to collect E7.5 or E3.5 embryos, respectively. Embryos were imaged as a group and carefully collected into individual tubes in the order presented, and then lysed for PCR genotyping using the primers mentioned above.

To prepare zygotes for siRNA microinjection or *in vitro* culture, B6D2F1 female mice aged 8 to 10 weeks were induced to superovulate with 7.5 IU pregnant mare serum gonadotropin (PMSG, Sigma-Aldrich), followed 48 h later by 7.5 IU human chorionic gonadotropin (hCG, Sigma-Aldrich). Females were mated with B6D2F1 males and killed at 20 h post hCG injection. Oviductal ampullae were dissected to release zygotes, and cumulus cells were removed by pipetting in M2 medium containing hyaluronidase (EMD Millipore). Zygotes were then washed in M2 medium (EMD Millipore) and cultured in KSOM medium (EMD Millipore) at 37°C in a humidified atmosphere of 5% CO₂/5% O₂ balanced in N₂.

Figure 1 (A) Schematic of *Med20* gene, CRISPR-Cas9-mediated deletion, genotyping primers for WT allele and Mut allele, RT-PCR primers (flanking intron2, which is 5691 bp) and three different siRNAs. F, forward; R, reverse. (B) Representative genotyped embryos at E7.5. (C) Representative genotyped embryos at E3.5. (D) The outgrowths produced by different genotypes. Outgrowths from WT and Het displayed a distinct ICM colony (red dashed line) surrounded by robustly proliferating trophoblast cells (blue dashed line). Scale bars, 100 μ m.

Outgrowth assay

Blastocysts were collected and transferred gently into culture plates (Nunc Delta, Thermo Fisher) and cultured in DMEM (Lonza, Allendale, NJ, USA) containing 10% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA, USA) and 1X GlutaMAX (Thermo Fisher). Outgrowth assay was conducted at 37°C in a humidified atmosphere of 5% CO₂ for 3 days. Outgrowths were then imaged and genotyped.

Immunofluorescence and confocal microscopy

Immunofluorescence was performed as previously described (Cui *et al.* 2016a,b). *In vivo* derived blastocysts were flushed at E3.5, and then cultured overnight before fixation and immunofluorescence (to ensure embryos had undergone EPI/PE/TE specification). *In vitro* blastocysts were harvested at 4 days post microinjection. Primary antibodies used in this study include: mouse anti-CDX2 (BioGenex, MU392A-UC); rabbit anti-NANOG (abcam, ab80892); rabbit anti-TRP53 (Cell Signaling Technology, #9284); goat anti-SOX17 (R&D Systems, AF1924); goat anti-OCT4 (abcam, ab27985). After secondary antibodies (Alexa Fluor, Life Technologies) and DAPI (Sigma) staining, embryos were transferred to chambered slides (BD Falcon) with one embryo per well for imaging. Embryos were imaged using Nikon A1 Spectral Detector Confocal with FLIM Module. Z-stacks (20X objective, 8 μ m sections) were collected and maximum projection was applied. Blastocysts collected from heterozygous intercrosses were imaged prior to knowledge of their genotypes. After imaging, embryos were individually recovered and lysed for genotyping.

Microinjection

Microinjection was performed as previously described (Cui *et al.* 2016a,b). A volume of 5–10 pL of 50 μ M Scrambled Control (5'-CAGGGTATCGACGATTACAAA, Qiagen) or *Med20* siRNA (siRNA1 target: 5'-CGCAGACGTTAATTTAATTAA, siRNA2 target: 5'-TACAGAGACATTTAACACAAA, siRNA3 target: 5'-CTCGGGAAAGCTGTTAATCTA, Qiagen, Fig. 1A) was microinjected into the cytoplasm of zygotes.

RNA extraction and reverse transcription PCR (RT-PCR)

Total RNA extraction was performed with a Roche High Pure RNA Isolation Kit (#11828665001). cDNA was synthesized using iScript cDNA synthesis kit (Bio-Rad Laboratories, 170-8891). Specific intron-spanning primers were used for RT-PCR (*Actb*: 5'-GGCCCAGAGCAAGAGAGGTATCC and 5'-ACGCACGATTTCCCTCTCAGC; *Med20*: 5'-AGTGGAG CTCCTACCAAGA and 5'-CCTTGGCACTCTGGAAGAAG, Fig. 1A).

Simultaneous extraction of RNA and DNA from single blastocyst

Blastocysts collected from heterozygous intercrosses were lysed individually (10 μ L lysis buffer per embryo) following the manual of Roche Kit (#11828665001), with DNase treatment step skipped. A volume of 13 μ L Elution Buffer was applied and the eluted mixture of RNA and DNA was used as follows: 6 μ L mixture for genotyping PCR with Platinum SuperFi Green PCR Master Mix (Thermo Fisher) and genotyping primers as listed above; the other 6 μ L mixture for cDNA synthesis using iScript cDNA synthesis kit (Bio-Rad, 170-8891). Regarding the resultant 8 μ L cDNA, 2 μ L was used for *Actb* RT-PCR and 6 μ L was used for *Med20* RT-PCR, with Platinum SuperFi PCR Mix (Thermo Fisher) and RT-PCR primers listed above.

Statistical analysis

All experiments were repeated at least three times. Percentage data were analyzed by ANOVA, and a value of $P < 0.05$ was considered statistically significant. Data are expressed as mean $\pm$ standard error of the mean.

Results

Med20 mutants cannot be recovered *in vivo* after E3.5

A CRISPR-mediated *Med20* knockout allele was generated for the Knockout Mouse Phenotyping Program (KOMP2) at The Jackson Laboratory. During

the initial phenotyping pipeline of The International Mouse Phenotyping Consortium (IMPC, <http://www.mousephenotype.org>), no homozygous *Med20* mutants were born, nor found at E15.5 or E9.5. Considering this, we first dissected embryos at E7.5 early post-gastrulation stage. Twenty-nine embryos were recovered from five heterozygous intercrosses and were genotyped. Genotyping results showed 20 Het and 9 WT embryos all with normal gastrulation morphology (Fig. 1B). No *Med20* mutant embryos were found at E7.5, nor were excessive empty decida ($n=6$), suggesting *Med20* mutants failed to implant. Therefore, we switched to collection and genotyping at the E3.5 blastocyst stage, where we recovered mutant *Med20* embryos at the expected Mendelian ratios. A total of 24 WT, 69 Het and 18 Mut embryos were found in 15 litters. Compared with WT and Het littermates, Mut blastocysts could not be identified by morphology alone (Fig. 1C). Combined, the normal blastocyst morphology plus the complete absence of mutants during gastrulation suggested implantation failure.

We next performed *in vitro* outgrowth assays, a technique used as a model for implantation (Armant 2005, Qin *et al.* 2005, Cui *et al.* 2016a). Another 42 blastocysts collected from six females were subjected to a 3-day outgrowth assay where each outgrowth was individually cultured, imaged and subsequently genotyped. As expected, successful hatching and outgrowth rates were high in both WT blastocysts (8/10, 80%) and Het blastocysts (21/23, 91.3%), displaying a distinct ICM colony surrounded by robustly proliferating trophoblast cells after 72 h in culture (Fig. 1D). However, all the mutant blastocysts failed to hatch or grow normally (0/9). Three of nine mutant blastocysts failed to hatch out of the zona pellucida (Fig. 1D, type I), two arrested during the process of hatching (type II), and four hatched free of the zona pellucida but did not form a monolayer of attached trophoblast cells (type III).

Each of these subtle phenotypes suggested impaired function of TE cells in mutant blastocysts, which lead to failures of hatching or implantation. These results are also consistent with a complete absence of mutant embryos at E7.5.

Med20 mutants have normal expression of OCT4 and CDX2

To explore the cause of the outgrowth and implantation failure, we first examined markers for apoptosis (TRP53) and first cell lineage choices including OCT4 for ICM and CDX2 for TE using immunofluorescence (IF). Blastocysts were collected, imaged and then genotyped. Of 25 blastocysts examined (5 WT, 15 Het, 5 Mut), all genotypes showed no apoptosis and normal robust expression of OCT4 in ICM and mutually exclusive expression of CDX2 in TE (Fig. 2). These results show that *Med20*-null blastocysts are not dying via apoptosis, and their ICM and TE have been appropriately specified.

Ectopic NANOG in *Med20* mutant TE

We next investigated the second cell-fate specification, the segregation of ICM into epiblast (EPI) and primitive endoderm (PE). Blastocysts were collected, assessed for NANOG and SOX17 localization (EPI and PE markers, respectively) via IF and then genotyped. From 31 blastocysts (8 WT, 16 Het, 7 Mut), all genotypes showed regular expression and localization of both SOX17 and CDX2. However, the majority of *Med20* mutant blastocysts (5/7, 71.4%) exhibited widespread ectopic expression of NANOG in TE cells (Fig. 3) compared with WT (1 from 8, 12.5%) and Het (2 from 16, 12.5%), suggesting that MED20 regulates early embryo development in part through repression of NANOG in CDX2-positive TE cells. Combined with the outgrowth failure of mutant embryos, we can conclude

Figure 2 Knockout of *Med20* did not affect apoptosis index or ICM/TE lineage specification. Blastocysts in this experiment were flushed at E3.5, and then cultured overnight before fixation and immunofluorescence. Blastocysts of all genotypes showed low apoptosis index (TRP53 as the marker) and that ICM cells were tightly arranged with robust expression of OCT4, while TE cells were uniformly arranged with specific expression of CDX2. Scale bar, 50 μ m.

Figure 3 Knockout of *Med20* did not affect the expression or localization of either SOX17 (marker of primitive endoderm) or CDX2 (marker of trophectoderm); however, KO of *Med20* led to severe ectopic expression of NANOG (marker of epiblast) in outside CDX2-positive TE cells. Blastocysts in this experiment were flushed at E3.5, and then cultured overnight before fixation and immunofluorescence. Scale bar, 50 μ m.

that deletion of *Med20* results in defective function of TE cells.

Med20 knockdown embryos phenocopy genetic knockout mutants

Due to the lack of available antibodies suitable for immunofluorescence, we examined the expression of *Med20* by RT-PCR to verify the success of both knockout and knockdown approaches (location of primers is shown in Fig. 1A). RT-PCR using cDNA from different stages of WT embryos shows that *Med20* is expressed at all preimplantation stages, from oocyte to blastocyst (Fig. 4A). We then extracted both RNA and DNA from single blastocysts to both genotype embryos and assess *Med20* expression (details in Material and methods section). As expected, genotyped mutant blastocysts

contain no *Med20* mRNA (Fig. 4B), confirming functional knockout of the deletion allele. To further verify the deletion phenotype was due to lack of MED20 and to establish a more efficient system to study MED20 function in embryos, three distinct commercial *Med20* siRNAs (Fig. 1A) were individually microinjected into zygotes. Satisfactory KD efficiency was confirmed at early morula stage (2 days after microinjection) with each siRNA (Fig. 4C). Similar to KO phenotype, KD of *Med20* did not affect blastocyst formation or morphology, but resulted in overall outgrowth failure (Fig. 4D).

KD of Med20 also induces severe ectopic NANOG expression in TE cells

Considering the overlapping expression of NANOG+CDX2 observed in *Med20* KO blastocysts, we also performed

Figure 4 (A) Expression pattern of *Med20* in WT preimplantation embryos. *Actb* was used as loading control. Oo, metaphase II oocyte; Zy, zygote; 2C, 2-cell embryo; 4/8C, mix of 4- and 8-cell stage embryos; Mo, morula; Blas, blastocyst. (B) Simultaneous extraction of both RNA and DNA from single blastocyst to perform both genotyping PCR and *Med20* RT-PCR, confirming KO was successful. *Actb* was used as loading control. (C) Endogenous *Med20* mRNA was significantly depleted by three distinct siRNAs after microinjection. (D) KD of *Med20* using distinct siRNAs did not affect blastocyst formation or morphology, but significantly altered embryo outgrowth potential. Red and blue dashed lines indicate ICM colony and trophoblast cells, respectively. Control: scrambled siRNA. *n*, number of embryos; *, $P < 0.05$. Scale bars, 100 μ m.

Figure 5 Knockdown of *Med20* by three distinct siRNAs did not affect the expression or localization of either SOX17 (primitive endoderm marker) or CDX2 (trophectoderm marker), but resulted in ectopic expression of NANOG in CDX2-positive TE cells. Blastocysts in this experiment were harvested at 4 days post microinjection, and then fixed for immunofluorescence. Scale bar, 50 μ m.

lineage specification assessment in KD blastocysts. Compared with control embryos (Fig. 5), KD of *Med20* does not alter SOX17 (PE) or CDX2 (TE) localization. However, as with KO embryos, ectopic NANOG in outer TE cells was detected in all KD groups (ectopic NANOG rate: Control, 2 from 19, 10.5%; siRNA1, 16 from 20, 80%; siRNA2, 16 from 18, 88.9%; siRNA3, 15 from 16, 93.8%), indicating that phenotypes of CRISPR-Cas9-mediated *Med20* KO can be fully recapitulated by microinjection of single *Med20* siRNAs. Importantly, these results confirm that loss of MED20 results in TE defects and outgrowth failure *in vivo* and *in vitro*.

Discussion

Cell differentiation and lineage specification is a complex and highly regulated process during development of all multicellular eukaryotic organisms. To obtain unique profiles of gene expression and distinct cellular identity, complexity in transcriptional control between regulatory elements and RNA polymerase must exist. Among these complicated networks, the Mediator complex is a key component of the RNA polymerase II (Pol II) transcriptional machinery. It can convey distal regulatory information to basal Pol II transcription machinery, playing a crucial role in not only activation, but also repression of eukaryotic mRNA synthesis (Beyer *et al.* 2007). The Mediator complex was originally detected in yeast, and then it was identified in mammalian species comprising up to 30 subunits (Tsai *et al.* 2014). Though the whole Mediator complex is required for all tissues and cell lineages, different Mediator subunits have distinct target genes, and phenotypes of individual

subunit mutants can be distinct from each other (Westerling *et al.* 2007), indicating a multifaceted role of Mediator complex during organismal development.

Though it is generally believed that the head module of Mediator is involved in interactions with the core Pol II machinery, studies have demonstrated that some regulators can directly target subunits in the head module, for example, Med17 (Park *et al.* 2001). Med20, another core component in head module, has not been well studied yet. The function of Med20 has been restricted to the regulation of tRNA and some non-coding RNAs transcription in fission yeast (Carlsten *et al.* 2016). In plants, Med20 controls the balance of salicylic acid- and jasmonate-associated defense pathways (Fallath *et al.* 2017). The role of MED20 in mammalian development has not been studied. In this study, we took advantage of both KO and KD strategies to demonstrate that MED20 is essential for early mouse development. Consistent with our findings, other Mediator subunits also exhibit specific embryonic lethal phenotypes; however, only CDK8 and MED21 have similar early lethality with all other documented mutants showing post-gastrulation phenotypes (reviewed in Yin & Wang 2014).

Our studies revealed ectopic NANOG (epiblast marker) expression in CDX2-positive TE cells of *Med20* KO and KD blastocysts. It is well established that CDX2 is essential for segregation of ICM and TE lineages at the blastocyst stage by repressing OCT4 and NANOG in the TE, although the detailed mechanism underlying this repression is still largely unknown (Strumpf *et al.* 2005, Niwa *et al.* 2005, Wang *et al.* 2010, Carey *et al.* 2015, Piliszek *et al.* 2017, Bassalart *et al.* 2018). Interestingly, in our study, both KO and KD of *Med20* only causes ectopic NANOG in

the outer TE cells, without effects on OCT4 expression or localization, suggesting that CDX2 represses OCT4, at least partially, through different pathways. Indeed, previous studies have illustrated that OCT4 can bind to the *Nanog* promoter, and this cis-regulatory machinery is essential for *Nanog* pluripotent transcription, suggesting OCT4 is at the top of this regulatory hierarchy (Kuroda *et al.* 2005, Rodda *et al.* 2005).

Embryonic stem (ES) cells have been used extensively to explore the functions of Mediator complex in cell lineage commitment. For example, a functional role of MED12 in the regulation of *Nanog* expression and maintenance of ES cell pluripotency has been debated (Tutter *et al.* 2009, Rocha *et al.* 2010), and mounting evidence indicates that MED12 and MED1, together with cohesin complex and loading factor, can contribute to ES cell state through DNA loops that directly link enhancers and promoters (Kagey *et al.* 2010, Apostolou *et al.* 2013, Phillips-Cremins *et al.* 2013). Additionally, many Mediator subunits have been identified as regulators of ES cell maintenance: MED6, MED7, MED10, MED12, MED14, MED15, MED17, MED21, MED24, MED27, MED28 and MED30 (Kagey *et al.* 2010).

Our results suggest that unlike these other subunits, MED20 is essential for repression of NANOG in TE cells to maintain TE identity and function. However, the exact mechanism by which MED20 and/or Mediator coordinates multiple TFs and co-factors to regulate NANOG expression is unknown. Complicating any mechanistic conclusions are studies that have shown certain Mediator subunits have selective affinity among different activators and TFs, such that the absence of MED20 may allow for Mediator interaction with activators of *Nanog* and other loci (Niwa 2014, Yin & Wang 2014, Miao *et al.* 2018). Other novel functions of Mediator have recently been documented. For example, it can interact directly with non-coding RNAs to influence transcription (Carlsten *et al.* 2013), regulate alternative mRNA processing (Huang *et al.* 2012) and alter epigenetic silencing of selected genes (Ding *et al.* 2008). In order to fully understand the mechanism and specificity of *Med20* function, we will likely need to assess transcriptome wide effects specifically in TE cells of KO or KD embryos. Alternatively, trophoblast stem cells may serve as a good model to explore MED20 function; however, *in vivo* results may differ from *in vitro* cell line studies.

In summary, using both KO and KD strategies, our study suggests that MED20 plays a significant role in proper trophoblast development that is essential for hatching and implantation. In addition, MED20 is indispensable for repression of NANOG in TE cells during early murine development to maintain TE identity and function.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by R01HD083311 to J M and J A R-P and faculty start-up fund to W C.

Acknowledgement

The authors thank the Knockout Mouse Phenotyping Program (KOMP2) and The Jackson Laboratory for providing *Med20*-knockout allele. They thank Yuran Tsuchida for assistance in genotyping. The confocal microscopy data were gathered in the Light Microscopy Facility and Nikon Center of Excellence at the Institute for Applied Life Sciences, UMass Amherst with support from the Massachusetts Life Sciences Center.

References

- Apostolou E, Ferrari F, Walsh RM, Bar-Nur O, Stadtfeld M, Cheloufi S, Stuart HT, Polo JM, Ohsumi TK, Borowsky ML *et al.* 2013 Genome-wide chromatin interactions of the Nanog locus in pluripotency, differentiation, and reprogramming. *Cell Stem Cell* **12** 699–712. (<https://doi.org/10.1016/j.stem.2013.04.013>)
- Armant DR 2005 Blastocysts don't go it alone. Extrinsic signals fine-tune the intrinsic developmental program of trophoblast cells. *Developmental Biology* **280** 260–280. (<https://doi.org/10.1016/j.ydbio.2005.02.009>)
- Arnold SJ & Robertson EJ 2009 Making a commitment: cell lineage allocation and axis patterning in the early mouse embryo. *Nature Reviews Molecular Cell Biology* **10** 91–103. (<https://doi.org/10.1038/nrm2618>)
- Bassalart C, Valverde-Estrella L & Chazaud C 2018 Primitive endoderm differentiation: from specification to epithelialization. *Current Topics in Developmental Biology* **128** 81–104. (<https://doi.org/10.1016/bs.ctdb.2017.12.001>)
- Beyer KS, Beauchamp RL, Lee MF, Gusella JF, Naar AM & Ramesh V 2007 Mediator subunit MED28 (Magin) is a repressor of smooth muscle cell differentiation. *Journal of Biological Chemistry* **282** 32152–32157. (<https://doi.org/10.1074/jbc.M706592200>)
- Cao Z, Carey TS, Ganguly A, Wilson CA, Paul S & Knott JG 2015 Transcription factor AP-2gamma induces early Cdx2 expression and represses HIPPO signaling to specify the trophoblast lineage. *Development* **142** 1606–1615. (<https://doi.org/10.1242/dev.120238>)
- Carey TS, Cao Z, Choi I, Ganguly A, Wilson CA, Paul S & Knott JG 2015 BRG1 governs nanog transcription in early mouse embryos and embryonic stem cells via antagonism of histone H3 lysine 9/14 acetylation. *Molecular and Cellular Biology* **35** 4158–4169. (<https://doi.org/10.1128/MCB.00546-15>)
- Carlsten JO, Zhu X & Gustafsson CM 2013 The multitasking Mediator complex. *Trends in Biochemical Sciences* **38** 531–537. (<https://doi.org/10.1016/j.tibs.2013.08.007>)
- Carlsten JO, Zhu X, Lopez MD, Samuelsson T & Gustafsson CM 2016 Loss of the Mediator subunit Med20 affects transcription of tRNA and other non-coding RNA genes in fission yeast. *Biochimica et Biophysica Acta* **1859** 339–347. (<https://doi.org/10.1016/j.bbaggm.2015.11.007>)
- Cockburn K & Rossant J 2010 Making the blastocyst: lessons from the mouse. *Journal of Clinical Investigation* **120** 995–1003. (<https://doi.org/10.1172/JCI41229>)
- Cui W, Dai X, Marcho C, Han Z, Zhang K, Tremblay KD & Mager J 2016a Towards functional annotation of the preimplantation transcriptome: an RNAi screen in mammalian embryos. *Scientific Reports* **6** 37396. (<https://doi.org/10.1038/srep37396>)
- Cui W, Pizzollo J, Han Z, Marcho C, Zhang K & Mager J 2016b Nop2 is required for mammalian preimplantation development. *Molecular Reproduction and Development* **83** 124–131. (<https://doi.org/10.1002/mrd.22600>)
- Cui W & Mager J 2018 Transcriptional regulation and genes involved in first lineage specification during preimplantation development. *Advances in Anatomy, Embryology and Cell Biology* **229** 31–46. (https://doi.org/10.1007/978-3-319-63187-5_4)
- Ding N, Zhou H, Esteve PO, Chin HG, Kim S, Xu X, Joseph SM, Friez MJ, Schwartz CE, Pradhan S *et al.* 2008 Mediator links epigenetic silencing

- of neuronal gene expression with x-linked mental retardation. *Molecular Cell* **31** 347–359. (<https://doi.org/10.1016/j.molcel.2008.05.023>)
- Fallath T, Kidd BN, Stiller J, Davoine C, Bjorklund S, Manners JM, Kazan K & Schenk PM 2017 MEDIATOR18 and MEDIATOR20 confer susceptibility to *Fusarium oxysporum* in *Arabidopsis thaliana*. *PLoS ONE* **12** e0176022. (<https://doi.org/10.1371/journal.pone.0176022>)
- Frum T & Ralston A 2015 Cell signaling and transcription factors regulating cell fate during formation of the mouse blastocyst. *Trends in Genetics* **31** 402–410. (<https://doi.org/10.1016/j.tig.2015.04.002>)
- Hentges KE 2011 Mediator complex proteins are required for diverse developmental processes. *Seminars in Cell and Developmental Biology* **22** 769–775. (<https://doi.org/10.1016/j.semcdb.2011.07.025>)
- Huang Y, Li W, Yao X, Lin QJ, Yin JW, Liang Y, Heiner M, Tian B, Hui J & Wang G 2012 Mediator complex regulates alternative mRNA processing via the MED23 subunit. *Molecular Cell* **45** 459–469. (<https://doi.org/10.1016/j.molcel.2011.12.022>)
- Kagey MH, Newman JJ, Bilodeau S, Zhan Y, Orlando DA, van Berkum NL, Elmeier CC, Goossens J, Rahl PB, Levine SS *et al.* 2010 Mediator and cohesin connect gene expression and chromatin architecture. *Nature* **467** 430–435. (<https://doi.org/10.1038/nature09380>)
- Kelleher RJ 3rd, Flanagan PM & Kornberg RD 1990 A novel mediator between activator proteins and the RNA polymerase II transcription apparatus. *Cell* **61** 1209–1215. ([https://doi.org/10.1016/0092-8674\(90\)90685-8](https://doi.org/10.1016/0092-8674(90)90685-8))
- Kornberg RD 2005 Mediator and the mechanism of transcriptional activation. *Trends in Biochemical Sciences* **30** 235–239. (<https://doi.org/10.1016/j.tibs.2005.03.011>)
- Kuroda T, Tada M, Kubota H, Kimura H, Hatano SY, Suemori H, Nakatsuji N & Tada T 2005 Octamer and Sox elements are required for transcriptional cis regulation of Nanog gene expression. *Molecular and Cellular Biology* **25** 2475–2485. (<https://doi.org/10.1128/MCB.25.6.2475-2485.2005>)
- Latham KE, Solter D & Schultz RM 1991 Activation of a two-cell stage-specific gene following transfer of heterologous nuclei into enucleated mouse embryos. *Molecular Reproduction and Development* **30** 182–186. (<https://doi.org/10.1002/mrd.1080300303>)
- Leung CY, Zhu M & Zernicka-Goetz M 2016 Polarity in cell-fate acquisition in the early mouse embryo. *Current Topics in Developmental Biology* **120** 203–234. (<https://doi.org/10.1016/bs.ctdb.2016.04.008>)
- Lokken AA & Ralston A 2016 The genetic regulation of cell fate during preimplantation mouse development. *Current Topics in Developmental Biology* **120** 173–202. (<https://doi.org/10.1016/bs.ctdb.2016.04.006>)
- Marcho C, Cui W & Mager J 2015 Epigenetic dynamics during preimplantation development. *Reproduction* **150** R109–R120. (<https://doi.org/10.1530/REP-15-0180>)
- Miao YL, Gambini A, Zhang Y, Padilla-Banks E, Jefferson WN, Bernhardt ML, Huang W, Li L & Williams CJ 2018 Mediator complex component MED13 regulates zygotic genome activation and is required for postimplantation development in the mouse. *Biology of Reproduction* **98** 449–464. (<https://doi.org/10.1093/biolre/iox004>)
- Molotkov A & Soriano P 2018 Distinct mechanisms for PDGF and FGF signaling in primitive endoderm development. *Developmental Biology* **442** 155–161. (<https://doi.org/10.1016/j.ydbio.2018.07.010>)
- Morgani SM, Metzger JJ, Nichols J, Siggia ED & Hadjantonakis AK 2018 Micropattern differentiation of mouse pluripotent stem cells recapitulates embryo regionalized cell fate patterning. *Elife* **7**. (<https://doi.org/10.7554/eLife.32839>)
- Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Scholer H & Smith A 1998 Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. *Cell* **95** 379–391. ([https://doi.org/10.1016/S0092-8674\(00\)81769-9](https://doi.org/10.1016/S0092-8674(00)81769-9))
- Niwa H 2014 The pluripotency transcription factor network at work in reprogramming. *Current Opinion in Genetics and Development* **28** 25–31. (<https://doi.org/10.1016/j.gde.2014.08.004>)
- Niwa H, Toyooka Y, Shimosato D, Strumpf D, Takahashi K, Yagi R & Rossant J 2005 Interaction between Oct3/4 and Cdx2 determines trophoblast differentiation. *Cell* **123** 917–929. (<https://doi.org/10.1016/j.cell.2005.08.040>)
- Park JM, Werner J, Kim JM, Lis JT & Kim YJ 2001 Mediator, not holoenzyme, is directly recruited to the heat shock promoter by HSF upon heat shock. *Molecular Cell* **8** 9–19. ([https://doi.org/10.1016/S1097-2765\(01\)00296-9](https://doi.org/10.1016/S1097-2765(01)00296-9))
- Paul S & Knott JG 2014 Epigenetic control of cell fate in mouse blastocysts: the role of covalent histone modifications and chromatin remodeling. *Molecular Reproduction and Development* **81** 171–182. (<https://doi.org/10.1002/mrd.22219>)
- Phillips-Cremens JE, Sauria ME, Sanyal A, Gerasimova TI, Lajoie BR, Bell JS, Ong CT, Hookway TA, Guo C, Sun Y *et al.* 2013 Architectural protein subclasses shape 3D organization of genomes during lineage commitment. *Cell* **153** 1281–1295. (<https://doi.org/10.1016/j.cell.2013.04.053>)
- Piliszek A, Madeja ZE & Plusa B 2017 Suppression of ERK signalling abolishes primitive endoderm formation but does not promote pluripotency in rabbit embryo. *Development* **144** 3719–3730. (<https://doi.org/10.1242/dev.156406>)
- Qin J, Takahashi Y, Isuzugawa K, Imai M, Yamamoto S, Hirai Y & Imakawa K 2005 Regulation of embryo outgrowth by a morphogenic factor, epimorphin, in the mouse. *Molecular Reproduction and Development* **70** 455–463. (<https://doi.org/10.1002/mrd.20225>)
- Ralston A, Cox BJ, Nishioka N, Sasaki H, Chea E, Rugg-Gunn P, Guo C, Robson P, Draper JS & Rossant J 2010 Gata3 regulates trophoblast development downstream of Tead4 and in parallel to Cdx2. *Development* **137** 395–403. (<https://doi.org/10.1242/dev.038828>)
- Rayon T, Menchero S, Nieto A, Xenopoulos P, Crespo M, Cockburn K, Canon S, Sasaki H, Hadjantonakis AK, de la Pompa JL *et al.* 2014 Notch and hippo converge on Cdx2 to specify the trophoblast lineage in the mouse blastocyst. *Developmental Cell* **30** 410–422. (<https://doi.org/10.1016/j.devcel.2014.06.019>)
- Risley MD, Clowes C, Yu M, Mitchell K & Hentges KE 2010 The Mediator complex protein Med31 is required for embryonic growth and cell proliferation during mammalian development. *Developmental Biology* **342** 146–156. (<https://doi.org/10.1016/j.ydbio.2010.03.019>)
- Rocha PP, Scholze M, Bleiss W & Schrewe H 2010 Med12 is essential for early mouse development and for canonical Wnt and Wnt/PCP signaling. *Development* **137** 2723–2731. (<https://doi.org/10.1242/dev.053660>)
- Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH & Robson P 2005 Transcriptional regulation of nanog by OCT4 and SOX2. *Journal of Biological Chemistry* **280** 24731–24737. (<https://doi.org/10.1074/jbc.M502573200>)
- Strumpf D, Mao CA, Yamanaka Y, Ralston A, Chawengsaksophak K, Beck F & Rossant J 2005 Cdx2 is required for correct cell fate specification and differentiation of trophoblast in the mouse blastocyst. *Development* **132** 2093–2102. (<https://doi.org/10.1242/dev.01801>)
- Tsai KL, Tomomori-Sato C, Sato S, Conaway RC, Conaway JW & Asturias FJ 2014 Subunit architecture and functional modular rearrangements of the transcriptional mediator complex. *Cell* **157** 1430–1444. (<https://doi.org/10.1016/j.cell.2014.05.015>)
- Tutter AV, Kowalski MP, Baltus GA, Iourgenko V, Labow M, Li E & Kadam S 2009 Role for Med12 in regulation of Nanog and Nanog target genes. *Journal of Biological Chemistry* **284** 3709–3718. (<https://doi.org/10.1074/jbc.M805677200>)
- Wang K, Sengupta S, Magnani L, Wilson CA, Henry RW & Knott JG 2010 Brg1 is required for Cdx2-mediated repression of Oct4 expression in mouse blastocysts. *PLoS ONE* **5** e10622. (<https://doi.org/10.1371/journal.pone.0010622>)
- Westerling T, Kuuluvainen E & Makela TP 2007 Cdk8 is essential for preimplantation mouse development. *Molecular and Cellular Biology* **27** 6177–6182. (<https://doi.org/10.1128/MCB.01302-06>)
- Wicklow E, Blij S, Frum T, Hirate Y, Lang RA, Sasaki H & Ralston A 2014 HIPPO pathway members restrict SOX2 to the inner cell mass where it promotes ICM fates in the mouse blastocyst. *PLoS Genetics* **10** e1004618. (<https://doi.org/10.1371/journal.pgen.1004618>)
- Yagi R, Kohn MJ, Karavanova I, Kaneko KJ, Vullhorst D, DePamphilis ML & Buonanno A 2007 Transcription factor TEAD4 specifies the trophoblast lineage at the beginning of mammalian development. *Development* **134** 3827–3836. (<https://doi.org/10.1242/dev.010223>)
- Yin JW & Wang G 2014 The Mediator complex: a master coordinator of transcription and cell lineage development. *Development* **141** 977–987. (<https://doi.org/10.1242/dev.098392>)

Received 25 September 2018

First decision 19 October 2018

Revised manuscript received 14 November 2018

Accepted 17 December 2018